Summit Therapeutics Currently Down Seven Days Straight, On Pace for Longest Losing Streak Since February 2023 -- Data Talk

Dow Jones11-21

Summit Therapeutics Inc. ( SMMT ) is currently at $16.12, down $0.44 or 2.66%

 

--Would be lowest close since Sept. 6, 2024, when it closed at $12.27

--On pace for largest percent decrease since Nov. 17, 2025, when it fell 5.99%

--Currently down seven consecutive days; down 15.87% over this period

--Longest losing streak since Feb. 13, 2023, when it fell for seven straight trading days

--Worst seven day stretch since the seven days ending Oct. 22, 2025, when it fell 16.44%

--Down 14.75% month-to-date

--Down 9.67% year-to-date; on pace for worst year since 2023, when it fell 38.59%

--Down 56.08% from its all-time closing high of $36.70 on April 24, 2025

--Down 12.49% from 52 weeks ago (Nov. 21, 2024), when it closed at $18.42

--Down 56.08% from its 52-week closing high of $36.70 on April 24, 2025

--Would be a new 52-week closing low

--Traded as low as $15.88; lowest intraday level since April 9, 2025, when it hit $15.78

--Down 4.11% at today's intraday low

 

All data as of 2:34:38 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 20, 2025 14:38 ET (19:38 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment